Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents.
immune checkpoint inhibitors
microsatellite instability
ovarian clear cell carcinoma
ovarian endometrioid carcinoma
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
07 Apr 2022
07 Apr 2022
Historique:
received:
03
02
2022
revised:
22
03
2022
accepted:
31
03
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Ovarian cancer has the highest mortality rate among all gynecological malignancies; therefore, a novel treatment strategy is needed urgently. Utilizing immune checkpoint inhibitors has been considered for microsatellite instability (MSI)-high (MSI-H) tumors. However, the prevalence of MSI-H tumors in ovarian endometrioid and clear cell carcinomas remains unclear. Here, polymerase chain reaction was used to analyze 91 cases of ovarian endometrioid and clear cell carcinomas for the MSI status and the relationship between MSI-H, immune checkpoint molecules, and clinicopathological factors (including patient survival). Only 5 of 91 (5%) cases were MSI-H endometrioid carcinomas. In these cases, CD-8 expression was significantly higher (
Identifiants
pubmed: 35455871
pii: healthcare10040694
doi: 10.3390/healthcare10040694
pmc: PMC9032309
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : JSPS KAKENHI
ID : 18K09229, 18K09291
Références
Br J Cancer. 2016 Jun 28;115(1):25-33
pubmed: 27228287
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
EXCLI J. 2018 Jan 22;17:159-168
pubmed: 29743854
Front Oncol. 2019 May 14;9:396
pubmed: 31139574
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
Adv Anat Pathol. 2013 Jan;20(1):45-52
pubmed: 23232571
N Engl J Med. 2019 Mar 28;380(13):1256-1266
pubmed: 30917260
Cancer Res. 2015 Dec 1;75(23):5034-45
pubmed: 26573793
Oncoimmunology. 2017 Jan 6;6(2):e1277308
pubmed: 28344892
Cell Immunol. 2019 Sep;343:103753
pubmed: 29395859
J Exp Clin Cancer Res. 2019 Jun 13;38(1):255
pubmed: 31196207
Am J Surg Pathol. 2012 Feb;36(2):163-72
pubmed: 22189970
Cancer. 2001 Jun 15;91(12):2417-22
pubmed: 11413533
PLoS One. 2019 Feb 27;14(2):e0212513
pubmed: 30811474
J Surg Oncol. 2014 Aug;110(2):129-35
pubmed: 24737677
Genet Test Mol Biomarkers. 2014 Apr;18(4):229-35
pubmed: 24592941
Oncotarget. 2018 Feb 22;9(19):14754-14763
pubmed: 29599905
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Int J Gynecol Pathol. 2006 Jul;25(3):223-9
pubmed: 16810057
Clin Cancer Res. 2016 Jun 15;22(12):3025-36
pubmed: 27306793
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
Diagnostics (Basel). 2019 Dec 27;10(1):
pubmed: 31892193
Ann Surg Oncol. 2016 Mar;23(3):943-50
pubmed: 26530444
Gynecol Oncol. 2012 Jan;124(1):164-9
pubmed: 22032835
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Hematol Oncol. 2019 May 31;12(1):54
pubmed: 31151482
Eur J Surg Oncol. 2016 Nov;42(11):1680-1686
pubmed: 27370895
Histopathology. 2016 Aug;69(2):288-97
pubmed: 26799366
Eur J Gynaecol Oncol. 2015;36(6):681-4
pubmed: 26775351
N Engl J Med. 2022 Feb 3;386(5):437-448
pubmed: 35045221
J Clin Oncol. 2006 Jan 10;24(2):241-51
pubmed: 16330668
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Nat Med. 2018 May;24(5):556-562
pubmed: 29736026
JAMA Oncol. 2019 Dec 1;5(12):1731-1738
pubmed: 31600397
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Mol Clin Oncol. 2015 May;3(3):699-705
pubmed: 26137290
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
pubmed: 24219974
J Gynecol Oncol. 2019 Jul;30(4):e56
pubmed: 31074244
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Oncotarget. 2017 May 31;8(57):97671-97682
pubmed: 29228642
Gynecol Oncol. 2019 Feb;152(2):243-250
pubmed: 30522700
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254